India to United States: Mitomycin Export Trade Route
India has recorded 96 verified shipments of Mitomycin exported to United States, representing a combined trade value of $4.4M USD. This corridor is served by 16 active Indian exporters, with an average shipment value of $45.4K USD. The leading Indian exporter is INTAS PHARMACEUTICALS LIMITED, which accounts for 45% of total export value with 21 shipments worth $2.0M USD. On the buying side, RX CROSSROADS 3PL LLC is the largest importer in United States with $1.2M USD in purchases. The top 3 suppliers — INTAS PHARMACEUTICALS LIMITED, MYLAN LABORATORIES LIMITED, EUGIA PHARMA SPECIALITIES LIMITED — together control 96% of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to United States Mitomycin corridor is one of India's established pharmaceutical export routes, with 96 shipments documented worth a combined $4.4M USD. The route is dominated by INTAS PHARMACEUTICALS LIMITED, which alone accounts for roughly 45% of all export value, reflecting the consolidated nature of India's mitomycin manufacturing sector.
Across 16 active suppliers, the average shipment value stands at $45.4K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 80% of all shipments, consistent with mitomycin's non-urgent bulk-order profile.
Shipment activity peaks during July–September, with an average transit time of 21 days port-to-port. The route has recorded an annual growth rate of 31.8%, placing it at rank #19 among India's top mitomycin export destinations globally.
On the import side, key buyers of Indian mitomycin in United States include RX CROSSROADS 3PL LLC, TO THE ORDER, RxCROSSROADS 3PL LLC and 30 others. RX CROSSROADS 3PL LLC is the single largest importer with 16 shipments valued at $1.2M USD.
Route Characteristics
- Average transit21 days
- Peak seasonQ3
- Primary modeSea freight
- Top portSAHAR AIR
Market Position
- Global rank#19
- Annual growth+31.8%
- Demand growth+28.3%
- Regulatory ease84/100
Top 10 Indian Mitomycin Exporters to United States
Showing top 10 of 16 Indian suppliers exporting Mitomycin to United States, ranked by total trade value (USD)
| Rank | Supplier (Indian Exporter) | Shipments | Total Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LIMITED Avg $94.1K per shipment | 21 | $2.0M | 45.3% |
| 2 | MYLAN LABORATORIES LIMITED Avg $93.2K per shipment | 20 | $1.9M | 42.8% |
| 3 | EUGIA PHARMA SPECIALITIES LIMITED Avg $41.1K per shipment | 8 | $329.1K | 7.6% |
| 4 | APICORE PHARMACEUTICALS PRIVATE LIMITED Avg $146.5K per shipment | 1 | $146.5K | 3.4% |
| 5 | AADPRI OPHTHALMIC COMPANY Avg $1.6K per shipment | 9 | $14.0K | 0.3% |
| 6 | OCEAN PHARMACEUTICAL Avg $1.0K per shipment | 7 | $7.3K | 0.2% |
| 7 | ATLAS ENTERPRISES Avg $599 per shipment | 9 | $5.4K | 0.1% |
| 8 | KOIT BIOPHARMA PRIVATE LIMITED Avg $946 per shipment | 4 | $3.8K | 0.1% |
| 9 | AADPRI OPHTHALMIC COMPANY Avg $476 per shipment | 7 | $3.3K | 0.1% |
| 10 | DELON INC. Avg $2.8K per shipment | 1 | $2.8K | 0.1% |
This table shows the top 10 of 16 Indian companies exporting mitomycin to United States, ranked by total trade value. The listed exporters are: INTAS PHARMACEUTICALS LIMITED, MYLAN LABORATORIES LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, APICORE PHARMACEUTICALS PRIVATE LIMITED, AADPRI OPHTHALMIC COMPANY, OCEAN PHARMACEUTICAL, ATLAS ENTERPRISES, KOIT BIOPHARMA PRIVATE LIMITED, AADPRI OPHTHALMIC COMPANY, DELON INC.. INTAS PHARMACEUTICALS LIMITED is the dominant supplier with 21 shipments worth $2.0M USD, giving it a 45% market share. The top 3 suppliers together account for 96% of the total trade value on this route.
Showing top 10 of 16 total Indian exporters on the India to United States Mitomycin export route.
Top 10 Mitomycin Importers in United States
Showing top 10 of 33 known buyers in United States receiving Mitomycin shipments from India, ranked by import value
On the receiving end of this trade route, the leading importers of Indian mitomycin in United States include RX CROSSROADS 3PL LLC, TO THE ORDER, RxCROSSROADS 3PL LLC, FOUNDATION CARE, EUGIA US LLC, among 33 total buyers. The largest importer is RX CROSSROADS 3PL LLC, accounting for $1.2M USD across 16 shipments — representing 28% of all mitomycin imports from India on this route.
| Rank | Importer / Buyer | Shipments | Import Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | RX CROSSROADS 3PL LLC | 16 | $1.2M | 28.0% |
| 2 | TO THE ORDER | 5 | $1.0M | 24.0% |
| 3 | RxCROSSROADS 3PL LLC | 4 | $643.8K | 14.8% |
| 4 | FOUNDATION CARE | 3 | $432.5K | 9.9% |
| 5 | EUGIA US LLC | 5 | $242.5K | 5.6% |
| 6 | B BRAUN MEDICAL INC | 3 | $222.2K | 5.1% |
| 7 | M S RXCROSSROADS 3 PL LLC | 1 | $146.5K | 3.4% |
| 8 | FOUNDATION CARE. | 3 | $128.1K | 2.9% |
| 9 | EUGIA US LLC, | 3 | $86.6K | 2.0% |
| 10 | B. BRAUN MEDICAL INC. | 1 | $58.9K | 1.4% |
Showing top 10 of 33 Mitomycin importers in United States on this route.
Top 10 Mitomycin Formulations Imported by United States
Showing top 10 of 69 product formulations shipped on the India to United States Mitomycin route, ranked by trade value
United States imports a wide range of mitomycin formulations from India, spanning tablets, capsules, suspensions, and combination drugs. The top formulation — PHAR.DRUGS AND MED: MITOSOL 0.2MG/VIAL EYEDROP (MOBI-USA Mitomycin for Solution0.2MG EACH VIAL CONTAINS : MITOMYICIN US — accounts for $1.0M USD across 4 shipments. There are 69 distinct product descriptions in the dataset, reflecting the variety of dosage forms and strengths imported.
| Rank | Product Formulation | Shipments | Trade Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | PHAR.DRUGS AND MED: MITOSOL 0.2MG/VIAL EYEDROP (MOBI-USA Mitomycin for Solution0.2MG EACH VIAL CONTAINS : MITOMYICIN US | 4 | $1.0M | 24.0% |
| 2 | MITOMYCIN FOR INJECTION USP [20MG/VIAL] | 2 | $472.6K | 10.8% |
| 3 | PHA.DRU & MEDI, MITOSOL 0.2MG/VIALEYEDROP (MOBI-USA Mitomycin for Solution 0.2MG EACH VIAL CONTAINS : MITOMY | 2 | $280.3K | 6.4% |
| 4 | PH.DRU.& MED.: MITOSOL 0.2MG/VIAL EYE DROP MITOMYCIN FOR OPHTHALMIC SOLUTION 0.2MG/VIAL EACH VIAL CONT. MITOMYCIN USP 0 | 3 | $222.2K | 5.1% |
| 5 | PH.DRU.& MED.: MITOSOL 0.2MG/VIAL EYE DROP (MITOMYCIN FOR OPHTHALMIC SOLUTION 0.2MG/VIAL EACH VIAL CONT. MITOMYCIN USP 0 | 4 | $187.0K | 4.3% |
| 6 | MITOMYCIN FOR INJECTION USP [40MG/VIAL] | 2 | $171.2K | 3.9% |
| 7 | PHA.DRU & MEDI, MITOSOL 0.2MG/VIALEYEDROP(MOBI-USA Mitomycin for Solution 0.2MG EACH VIAL CONTAINS : MITOMYI | 1 | $152.1K | 3.5% |
| 8 | MITOMYCIN FOR INJ 40MG VIAL 1 SDV USP | 1 | $146.5K | 3.4% |
| 9 | MITOMYCIN FOI 20MG 1S US ARCHIS PHARMA (7802451) TAX VAL 8218214 | 1 | $98.5K | 2.3% |
| 10 | MITOMYCIN FOI 40MG 1S US ARCHIS PHARMA (7802449) TAX VAL 8105877.12 | 1 | $97.2K | 2.2% |
Showing top 10 of 69 Mitomycin formulations imported by United States on this route.
Shipping & Logistics Analysis
Freight mode split and port-of-origin breakdown
Freight Mode Distribution
Sea freight dominates at 80%, typical for bulk pharmaceutical shipments.
Top Ports of Origin
SAHAR AIR handles the highest volume with 25 shipments. Transit time averages 21 days by sea.
Market Dynamics
India's mitomycin exports to United States are driven primarily by a handful of large-scale manufacturers. INTAS PHARMACEUTICALS LIMITED with 21 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 16 active exporters signals a competitive but concentrated market — buyers in United States benefit from supplier diversity while the top tier handles the majority of volume.
The top 3 suppliers — INTAS PHARMACEUTICALS LIMITED, MYLAN LABORATORIES LIMITED, EUGIA PHARMA SPECIALITIES LIMITED — together account for 96% of total trade value on this route. The average shipment value of $45.4K USD reflects a mix of bulk commercial orders and smaller specialty shipments.
Beyond the primary product category, shipments on this route include closely related formulations such as mitomycin for injection usp [20mg/vial] and pha.dru & medi, mitosol 0.2mg/vialeyedrop (mobi-usa mitomycin for solution 0.2mg each vial contains : mitomy, suggesting that buyers in United States tend to consolidate orders across related product lines from the same Indian supplier.
On the buying side, RX CROSSROADS 3PL LLC is the largest importer with 16 shipments worth $1.2M USD — representing 28% of all mitomycin imports from India on this route. A total of 33 buyers are active on this corridor.
Route Statistics
- Trade Volume
- $4.4M
- Avg. Shipment
- $45.4K
- Suppliers
- 16
- Buyers
- 33
- Transit (Sea)
- ~21 days
- Annual Growth
- +31.8%
Reverse Direction
United States → India — Mitomycin (Import)Other Mitomycin Routes
Unlock the Full India to United States Mitomycin Dataset
TransData Nexus provides verified shipment-level records, supplier contact details, HS code breakdowns, real-time pricing benchmarks, and regulatory compliance guides for 96 shipments on this route.
Frequently Asked Questions — India to United States Mitomycin Trade
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which Indian companies export Mitomycin to United States?
The leading Indian exporters of Mitomycin to United States are INTAS PHARMACEUTICALS LIMITED, MYLAN LABORATORIES LIMITED, EUGIA PHARMA SPECIALITIES LIMITED. INTAS PHARMACEUTICALS LIMITED holds the largest market share at approximately 45% of total trade value on this route.
Q What is the total value of Mitomycin exports from India to United States?
India exports Mitomycin to United States worth approximately $4.4M USD across 96 recorded shipments. The average value per shipment is $45.4K USD.
Q Which ports does India use to ship Mitomycin to United States?
The most active port of origin is SAHAR AIR with 25 shipments. Indian exporters primarily use sea freight for this route, with 80% of shipments going by sea and 26% by air.
Q How long does shipping take from India to United States for Mitomycin?
The average transit time for Mitomycin shipments from India to United States is approximately 21 days. Sea freight typically takes longer, while air freight can reduce this significantly for urgent orders. Peak shipping activity is observed during July–September.
Q Is the India to United States Mitomycin trade route growing?
Yes — this trade corridor has seen an annual growth rate of approximately 31.8% with demand growth tracking at 28.3%. The route is ranked #19 among India's top Mitomycin export destinations globally.
Q How many suppliers are active on the India to United States Mitomycin route?
There are currently 16 active Indian suppliers exporting Mitomycin to United States. The market is moderately concentrated with INTAS PHARMACEUTICALS LIMITED accounting for 45% of total shipment value.
Q Who are the main importers of Mitomycin from India in United States?
The leading importers of Indian Mitomycin in United States include RX CROSSROADS 3PL LLC, TO THE ORDER, RxCROSSROADS 3PL LLC, FOUNDATION CARE, EUGIA US LLC. RX CROSSROADS 3PL LLC is the largest buyer with 16 shipments worth $1.2M USD.
Official References & Regulatory Resources
- India Trade Statistics (DGFT)
- Invest India — Pharma Sector
- WCO HS Nomenclature
- Ministry of Commerce — Pharma Exports
- Pharmexcil
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Route Identification: India to United States export trade corridor identified from Indian Customs (DGFT) records for Mitomycin.
- 2.Supplier/Buyer Matching: 16 Indian exporters and 33 importers in United States matched using name normalization.
- 3.Value Aggregation: Total export value aggregated from 96 verified shipping bill records. Values are FOB in USD.
- 4.Market Share Analysis: Each supplier and buyer contribution calculated as a percentage of total route value. Statistical normalization applied to ensure accurate representation across varying shipment sizes.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
96 Verified Shipments
16 Indian exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists